Patrick G. Lepore Purchases 15,000 Shares of VYNE Therapeutics Inc. (NASDAQ:VYNE) Stock

VYNE Therapeutics Inc. (NASDAQ:VYNE) Director Patrick G. Lepore acquired 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The stock was acquired at an average cost of $2.92 per share, with a total value of $43,800.00. Following the completion of the acquisition, the director now owns 51,472 shares in the company, valued at $150,298.24. This trade represents a 41.13 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

VYNE Therapeutics Price Performance

NASDAQ VYNE opened at $2.70 on Friday. The company’s 50 day simple moving average is $2.96 and its two-hundred day simple moving average is $2.35. VYNE Therapeutics Inc. has a 1 year low of $1.57 and a 1 year high of $4.30. The stock has a market capitalization of $39.83 million, a PE ratio of -3.14 and a beta of 1.30.

Analyst Ratings Changes

VYNE has been the subject of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $5.75 price target on shares of VYNE Therapeutics in a report on Tuesday. BTIG Research started coverage on VYNE Therapeutics in a research note on Monday, November 18th. They issued a “buy” rating and a $8.00 target price for the company.

Institutional Investors Weigh In On VYNE Therapeutics

An institutional investor recently bought a new position in VYNE Therapeutics stock. Lynx1 Capital Management LP purchased a new stake in VYNE Therapeutics Inc. (NASDAQ:VYNE) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 16,194 shares of the company’s stock, valued at approximately $32,000. VYNE Therapeutics makes up about 0.0% of Lynx1 Capital Management LP’s portfolio, making the stock its 17th largest holding. Lynx1 Capital Management LP owned approximately 0.11% of VYNE Therapeutics at the end of the most recent reporting period. 83.78% of the stock is currently owned by hedge funds and other institutional investors.

VYNE Therapeutics Company Profile

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.